|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Real-time-guided bone regeneration around standardized critical size calvarial defects using bone marrow-derived mesenchymal stem cells and collagen membrane with and without using tricalcium phosphate: an in vivo microcomputed tomographic and histologic e显示文摘The aim of the present real time in vivo micro-computed tomography(m CT)and histologic experiment was to assess the efficacy of guided bone regeneration(GBR)around standardized calvarial critical size defects(CSD)using bone marrow-derived mesenchymal stem cells(BMSCs),and collagen membrane(CM)with and without tricalcium phosphate(TCP)graft material.In the calvaria of nine female Sprague-Dawley rats,full-thickness CSD(diameter 4.6 mm)were created under general anesthesia.Treatment-wise,rats were divided into three groups.In group 1,CSD was covered with a resorbable CM;in group 2,BMSCs were filled in CSD and covered with CM;and in group 3,TCP soaked in BMSCs was placed in CSD and covered with CM.All defects were closed using resorbable sutures.Bone volume and bone mineral density of newly formed bone(NFB)and remaining TCP particles and rate of new bone formation was determined at baseline,2,4,6,and 10 weeks using in vivo m CT.At the 10th week,the rats were killed and calvarial segments were assessed histologically.The results showed that the hardness of NFB was similar to that of the native bone in groups 1 and 2 as compared to the NFB in group 3.Likewise,values for the modulus of elasticity were also significantly higher in group 3 compared to groups 1 and 2.This suggests that TCP when used in combination with BMSCs and without CM was unable to form bone of significant strength that could possibly provide mechanical'lock'between the natural bone and NFB.The use of BMSCs as adjuncts to conventional GBR initiated new bone formation as early as 2 weeks of treatment compared to when GBR is attempted without adjunct BMSC therapy. | Khalid Al-Hezaimi Sundar Ramalingam Mansour Al-Askar Aws S ArRejaie Nasser Nooh Fawad Jawad Abdullah Aldahmash Muhammad Atteya Cun-Yu Wang | 2016 | International Journal of Oral Science2016，8，1： | 2 |
| 2 | CD91 is a common receptor for heat shock proteins gp96, hspgO, hsp70, and calreticulin 显示文摘 | Basu S Binder R J Ramalingam T Srivastava PK | 2001 | Immunity2001，14，3： | 1 |
| 3 | CD91 is a common receptor for heat shock proteins gp96,hsp90,hsp70,and calreticulin显示文摘 | Basu S Binder RJ Ramalingam T | 2001 | Immunity2001，14，3： | 1 |
| 4 | Molecular epidemiology of HIV 显示文摘 | Kandathil A J Ramalingam S Kannangai R | 2005 | Indian J Med Res2005，12，1： | 1 |
| 5 | Vitamin d deficiency and insulin resistance in normal and type 2 diabetes subjects显示文摘 | Bachali S Dasu K Ramalingam K | 2013 | Indian J Clin Biochem2013，28，1： | 1 |
| 6 | Hazardous dichloromethane recovery in combined temperature and vacuum pressure swing adsorption process显示文摘 | RAMALINGAM S G SAUSSAC J PRIEE P | 2011 | Journal of Hazardous Materials2011，198，： | 1 |
| 7 | Meaningful survival in lung cancerpatients显示文摘 | Belani C | 2002 | Senlin Oncol2002，29，4： | 1 |
| 8 | Application of response surface methodology to optimize the process variables for reactive red and acid brown dye removal using a novel adsorbent显示文摘 | RAVIKUMAR K RAMALINGAM S KRISHNAN S | 2006 | Dyes and Pigmcnts2006，70，1： | 1 |
| 9 | CD91 is a common receptor for heat shock proteing gp96, hsp90, hsp70 and calreticulin显示文摘 | Basu S Binder R J Ramalingam J | 2001 | Immunity2001，14，3： | 1 |
| 10 | CD91 is a common receptor for heat shock protein gp96, hsp70, and calreticulin 显示文摘 | Basu S Binder RJ Ramalingam J | 2001 | Immunity2001，14，3： | 1 |
| 11 | Intraves ical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: A phase Ⅰ and pharrnacokinetic study显示文摘 | Ramalingam S Schoenberg MP | 2003 | J Clin Oncol2003，21，4： | 1 |
| 12 | Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599 显示文摘 | Ramalingam S S Dahlberg S E Langer C J | 2008 | J Clin Oncol2008，26，1： | 1 |
| 13 | A phase Ⅰ study of 171allylamino 17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies显示文摘 | Ramalingam S S Egorin M J Ramanathan R K | 2008 | Clin Cancer Res2008，14，11： | 1 |
| 14 | Systemic chemotherapy for advanced non-small cell lung cancer:recent advances and future directions 显示文摘 | Ramalingam S Belani C | 2008 | Oncologist2008，13，1： | 1 |
| 15 | Molecularly -targeted therapies for non - small cell lung cancer 显示文摘 | Ramalingam S Belani CP | 2005 | Expert Opin Pharmacother2005，6，15： | 1 |
| 16 | Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth,invasion and angiogenesis in vivo 显示文摘 | Ramachandran I Thavathiru E Ramalingam S | 2012 | Oncology2012，31，22： | 1 |
| 17 | A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in seeond-line therapy of advanced non-small cell lung cancer ( GALAXY-1 ) 显示文摘 | Ramalingam S Goss G Rosell R | 2015 | Ann Oncol2015，26，8： | 1 |
| 18 | Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer显示文摘 | Mohamed MK Ramalingam S Lin Y | 2005 | Ann Oncol2005，16，： | 1 |
| 19 | Quantitative assessment of the p55-Mdm2 feedback loop using protein lysate microarrays 显示文摘 | RAMALINGAM S HONKANEN P YOUNG L | 2007 | Cancer Research2007，67，13： | 1 |
| 20 | Lung cancer in youngpatients:analysis of a surveillance,epidemiology,and end resultsdatabase显示文摘 | Ramalingam S Pawlish K Gadgeel S | 1998 | J Clin Oncol1998，16，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员